RHYTHMONE
11.9.2019 07:32:09 CEST | Business Wire | Press release
RhythmOne , LLC, a Tremor International company, today announces it will be bringing the infrastructure, scale and success of its programmatic platform to the Asia-Pacific (APAC) and Latin American (LATAM) markets. The announcement will also be made at the international digital marketing conference DMEXCO, following the company’s successful expansion into Europe earlier this year.
To lead international expansion efforts, today the company also announces the appointment of industry veterans Assaf Suprasky as General Manager of Tremor International’s Israel operations and Gal Topaz as Senior Vice President, Exchange Operations and Business Development. Both executives come to RhythmOne with deep experience in advanced mobile and digital video advertising solutions. Prior to his role at RhythmOne, Suprasky was CEO at personalized advertising specialist myThings, and Topaz was the CEO of programmatic group Feature Forward. Physical business development and sales teams are also now in place and active in Europe, APAC, and LATAM.
The RhythmOne Programmatic Platform is among the world’s largest brand-safe programmatic platforms. Offering technological efficiency at virtually every stage of the process, the global platform helps to effectively connect buyers to sellers and engage consumers on formats spanning video, connected TV (CTV), in-app, and display. A proven leader in the US, the RhythmOne Programmatic Platform reaches 358.8 million uniques globally* and is directly integrated with 600+ premium publishers – resulting in over 10,000 properties. The April 2019 acquisition of RhythmOne by Tremor International (AIM: TRMR) has laid the groundwork for further expansion initiatives and enhancements to the platform, including leveraging the large geographical footprint of the group’s performance division by expanding the RhythmOne Programmatic Platform into Asia.
With brand safety at the heart of its offering – supported by RhythmGuard, RhythmOne’s proprietary brand safety technology – and consistent top-tier ratings in Pixalate’s Seller Trust Indexes for programmatic display, mobile, and video advertising both internationally and in the US, the RhythmOne Programmatic Platform helps deliver high-quality solutions with large scale, and is integrated with the major international players including Google Exchange Bidding and Amazon A9. For publishers, RhythmOne offers a fully-integrated supply monetization platform (SSP) to maximize the value of inventory across desktop, mobile, and connected TV devices. Powered by an enhanced technology stack, the RhythmOne SSP provides web publishers and app developers with full access to a global programmatic ad marketplace.
“We are proud to be hosting a large-scale presence at DMEXCO this year as we take our US success and bring it to the international stage in the Asia-Pacific and Latin American markets,” said Ofer Druker, CEO Tremor International. “Our platform has massive global reach, has unique features and partnerships, and, alongside our market-specific business development professionals, we provide the perfect combination of a world-class product with local support, giving us confidence in delivering our product on an international scale. We are also pleased to welcome Assaf Suprasky and Gal Topaz to the RhythmOne team and are confident that their expertise will help bolster our success by delivering results to both demand clients and supply partners on the global stage.”
*Quantcast Measure, August 2019 / 30 Day Total
-ENDS-
Notes to the editors
RhythmOne is top-rated in the most current Pixalate programmatic seller trust rankings (Q4 2018):
- #1 US and #4 International, Global Seller Trust Index
- #1 Mobile Seller Trust Index
- #1 US and #2 International, Video Seller Trust Index
Since 2018, RhythmOne has been partnered with AU-based Allegiant Media as a reseller for RhythmOne in Australia and New Zealand. RhythmOne will be continuing its partnership with them.
About Tremor International
Tremor International Ltd is a global leader in advertising technologies, operating in more than 70 countries. It has three core divisions: Tremor Video (brand advertising), RhythmOne (media) and Taptica (performance advertising).
RhythmOne drives real business outcomes in multiscreen advertising. Its highly-ranked programmatic platform efficiently and effectively delivers performance, quality, and actionable data to demand and supply-focused clients and partners – and its influencer marketing offering fosters action and awareness by connecting brands with influencers who create and distribute branded content to engaged consumers.
Tremor Video helps advertisers deliver impactful brand stories across all screens through the power of creative video intelligence—innovative video technology combined with advanced audience data and captivating creative. Tremor Video is one of the largest and most innovative video advertising companies in North America, with offerings in CTV, influencer marketing, and private marketplaces.
The Taptica performance business is an end-to-end mobile technology advertising platform that helps the world's top brands reach their most valuable users with the widest range of traffic sources available today. Its proprietary technology leverages big data to target quality media at scale. It works with more than 600 advertisers including Amazon, Alibaba, Bytedance, Netmarble, Stubhub and OpenTable.
Tremor International Ltd is headquartered in Israel and maintains offices throughout the US and Canada, Asia-Pacific, Europe, India, and Latin America, and is traded on the London Stock Exchange (AIM: TRMR).
Forward-Looking Statements
This press release contains forward-looking statements. In some cases, you can identify forward-looking statements by the words "may," “likely,” "will," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. All statements other than statements of historical fact are statements that could be forward-looking statements, including, but not limited to, statements about the potential and effectiveness of RhythmOne’s programmatic platform. These forward-looking statements are subject to risks and uncertainties, assumptions and other factors that could cause actual results and the timing of events to differ materially from future results that are expressed or implied in the forward-looking statements. Factors that could cause or contribute to such differences include the dynamic and rapidly evolving sector, as well as the highly competitive industry that RhythmOne operates in, which make it difficult to evaluate prospects. These and other risk factors are discussed in RhythmOne’s Annual Report for the period ended March 31, 2018. The forward-looking statements in this article are based on information available to RhythmOne as of the date hereof, and we assume no obligation to update any forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005104/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release
The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio
Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release
Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
